Takeda

This Phase 3 trial tested Takeda's dengue vaccine (TDV) in 480 healthy people aged 4 to 60 in India. Participants received two doses of either the vaccine or a placebo, three months apart. The main goals were to check for side effects and measure the body's immune response agains…

This study tested a dengue vaccine (TDV) in 187 healthy Japanese volunteers aged 4 to 60. Participants received two shots three months apart. The main goal was to see if the vaccine triggers an immune response against all four types of dengue virus. The trial is now complete.

This study tested a new dengue vaccine in over 20,000 healthy children aged 4 to 16 years. The goal was to see if two doses could prevent dengue fever caused by any of the four dengue virus types. The vaccine was given as a shot under the skin and compared to a placebo. Results s…

This phase 2 trial tested a tetravalent dengue vaccine (TDV) in 30 healthy adults, some with prior dengue exposure and some without. The goal was to measure the body's immune response and check for safety. Participants received a single shot, and researchers tracked antibody leve…

This completed Phase 3 study tested TAK-771, a combination of immune globulin and hyaluronidase, in 26 Japanese adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN). The main goals were to check for side effects and see…

This study tested a drug called TAK-755 in 29 adults with a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). The goal was to see if TAK-755, along with standard immune-suppressing drugs, could control the disease with little or no pl…

This early-stage study tested a drug called mezagitamab in 17 people with IgA nephropathy, a kidney disease. The main goal was to check for side effects and see how the body processes the drug. Participants received injections under the skin for several weeks and were monitored f…

This phase 2 trial tested whether TAK-341, given as an IV infusion every 4 weeks for a year, can slow the progression of multiple system atrophy (MSA), a rare and serious brain disorder. The study enrolled 158 adults with MSA across North America, Europe, and Asia. Researchers me…

This study looked at the long-term safety and effectiveness of the drug leuprorelin in 1,905 people with spinal and bulbar muscular atrophy (SBMA), a rare muscle-weakening disease. Participants were followed for up to 8 years in routine medical care. The main goals were to track …

This study checked the long-term safety of TAK-771 in 15 Japanese patients with primary immunodeficiency disease (PID). Participants received TAK-771 injections for up to 3 years. The main goal was to monitor side effects and immune reactions. The study is now complete.

This study looked at the long-term safety of vedolizumab, a biologic drug given by IV, in 59 children with ulcerative colitis or Crohn's disease. Participants had already completed a previous study and continued treatment to monitor for side effects. The goal was to see if the dr…

This completed Phase 3 trial tested whether the experimental drug zasocitinib works better than the approved drug deucravacitinib for moderate-to-severe plaque psoriasis. Over 600 participants took one tablet and one capsule daily for 16 weeks. The main goal was to see how many a…

This study tested a medicine called vedolizumab in 121 children with moderate to severe ulcerative colitis, a condition causing inflammation and pain in the gut. The goal was to see if the drug could help children achieve remission, meaning their symptoms improve and tests show l…

This phase 1b trial tested the safety of adding TAK-079 (Mezagitamab) to standard treatments for 50 people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal was to find the right dose and watch for side effects. Researchers also tracked how we…

This study tested a new drug called TAK-676, alone and with pembrolizumab, in 248 adults with advanced solid tumors that had no standard treatment options. The main goal was to check safety and find the highest dose that causes few side effects. The study also looked at how well …

This study followed 48 people with hereditary angioedema (HAE) in Poland who were taking lanadelumab as part of a national drug program. Researchers tracked how many participants remained attack-free over 24 months, how many attacks still needed rescue treatment, and the severity…

This Phase 2 trial tested whether TAK-101, given as an intravenous infusion, can reduce gluten-related symptoms and immune activation in adults with well-controlled celiac disease who follow a gluten-free diet. Participants received two doses of TAK-101 or placebo, and all were l…

This study tested three different starting doses (45 mg, 30 mg, and 15 mg daily) of the drug ponatinib in 283 adults with chronic phase chronic myeloid leukemia (CML) that had stopped responding to other treatments or had a specific genetic mutation (T315I). The main goal was to …

This completed study in Japan looked at the safety and effectiveness of the drug VPRIV (velaglucerase alfa) in 63 people with Gaucher disease. Participants were either new to treatment or switching from another Gaucher therapy. The main goal was to track side effects and serious …

This large phase 3 trial tested a new drug combination (brentuximab vedotin plus AVD) against the standard ABVD regimen in 1,334 patients with advanced Hodgkin lymphoma. The goal was to see if the new combo could delay cancer progression better. Results showed improved progressio…

This study tested a new medicine called TAK-881, a concentrated antibody solution given under the skin, in 65 people with primary immunodeficiency diseases (PIDD). The goal was to see how well the body absorbs it and if it is safe compared to an existing treatment (HYQVIA). Parti…

This phase 3 study tested TAK-625 (maralixibat) in 7 Japanese children with Alagille syndrome, a rare genetic liver disorder. The goal was to see if the drug reduces bile acid levels and itching, and to find the best dose. Participants took the drug daily for up to 34 months, wit…

This study reviewed medical records of 115 Chinese people with hereditary angioedema (HAE) to see how well two approved drugs work in real life. One drug, lanadelumab, is used to prevent attacks, and the other, icatibant, treats sudden attacks. Researchers measured attack rates a…

This study tested a drug called leuprorelin to control central precocious puberty, a condition where children start puberty too early. About 80 children received an injection every 12 weeks for 6 months. The goal was to suppress hormones that drive early puberty, helping children…

This study looked at side effects of the drug Cabometyx in 263 Japanese adults with advanced liver cancer that had worsened after other treatments. Doctors monitored participants for 12 months to record any serious or severe side effects. The goal was to understand the drug's saf…

This study monitored 688 people in South Korea with ulcerative colitis, Crohn's disease, or pouchitis who were treated with Kynteles (vedolizumab) as part of their normal care. The main goal was to track side effects, and researchers also looked at how many patients saw symptom i…

This study tested a new drug, TAK-981, combined with the immunotherapy pembrolizumab in 161 adults with advanced or metastatic solid tumors that could not be cured. The main goals were to check safety and see if the combination could shrink tumors. Participants received treatment…

This study tested an experimental oral drug called TAK-279 in 1,108 adults with moderate-to-severe plaque psoriasis. Participants received either TAK-279, a placebo, or an approved psoriasis drug (apremilast) for up to 69 weeks. The main goal was to see if TAK-279 could clear or …

This study tested whether adding pevonedistat to the standard drug azacitidine helps people with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or low-blast acute myeloid leukemia live longer without their disease getting worse. About 454 adults took part…

This Phase 3 study tested an experimental oral drug called TAK-279 in 693 adults with moderate-to-severe plaque psoriasis. Participants received either TAK-279, an approved treatment (apremilast), or a placebo for up to 61 weeks. The main goal was to see if TAK-279 reduces skin p…

This study tested whether adding a drug called pevonedistat to the standard two-drug combination (venetoclax and azacitidine) helps adults recently diagnosed with acute myeloid leukemia (AML) who are too frail for intensive chemotherapy. About 164 participants received either the…

This completed Phase 4 trial tested the drug brentuximab vedotin in 50 adults with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL), a rare blood cancer. Participants had already received at least one round of chemotherapy. The study measured how many patien…

This completed Phase 4 trial tested the drug brentuximab vedotin in 10 Chinese adults with a rare type of skin lymphoma called CD30-positive cutaneous T-cell lymphoma. The goal was to see if the drug could shrink or eliminate cancer for at least 4 months and to check for long-ter…

This phase 3 trial tested two targeted drugs, brigatinib and alectinib, in 248 people with advanced ALK-positive non-small-cell lung cancer whose cancer had worsened after taking crizotinib. Participants were randomly assigned to take either brigatinib or alectinib daily. The mai…

This completed study looked at the long-term safety and effectiveness of vedolizumab (Entyvio) in over 1,100 people with moderate to severe ulcerative colitis who had not responded well to other treatments. Researchers tracked side effects and how well the drug controlled disease…

This study looked at how safe and effective the blood pressure drug azilsartan is for children aged 6 to 16 with high blood pressure. Only 5 children took part, and doctors monitored them for side effects and blood pressure changes for up to 12 months. The goal was to gather real…

This early-phase trial tested an experimental drug called TAK-676 combined with the immunotherapy pembrolizumab after radiation therapy in 34 adults with advanced lung, breast, or head/neck cancers that had stopped responding to checkpoint inhibitors. The main goals were to check…

This study tested whether a new drug called TAK-063 can help people with schizophrenia who are having a sudden worsening of symptoms. 164 adults took either the drug or a placebo for 6 weeks. The main goal was to see if symptoms improved using a standard rating scale. The study i…

This study tested a drug called TAK-625 (maralixibat) in 5 Japanese children with progressive familial intrahepatic cholestasis (PFIC), a rare liver disease that causes severe itching. The main goal was to see if the drug reduces itching over 26 weeks. Researchers also checked sa…

This study in Japan looked at 32 children (ages 2 to under 18) with hereditary angioedema who received Firazyr injections for acute attacks. Researchers tracked side effects and how quickly symptoms resolved over 3 months. The goal was to gather real-world safety and effectivenes…

This study tested an experimental drug called TAK-861 in 105 adults with narcolepsy type 1, a condition causing severe daytime sleepiness and sudden muscle weakness (cataplexy). Participants took either TAK-861 or a placebo daily for 3 months. The main goal was to see if the drug…

This study follows 1,000 people with CD30-positive lymphoma who are already receiving or about to receive brentuximab vedotin as part of their normal care. Researchers will track side effects and how the drug is used in everyday practice, without giving any new treatment. The goa…

This completed Phase 1 trial enrolled 30 healthy adults aged 18-50 to compare how the body absorbs and clears two antibody treatments given as a single injection under the skin: TAK-881 and HyQvia. Participants stayed at the clinic for 8 days and had follow-up visits up to Day 85…

This early-stage study tested whether a single dose of TAK-063 could prevent brain activity changes and psychotic-like symptoms caused by ketamine in 27 healthy adult men. Researchers used brain scans to measure effects. The goal was to understand how TAK-063 works in the brain, …

This early-stage trial tested the safety and tolerability of multiple doses of TAK-063 in 77 participants, including people with stable schizophrenia and healthy Japanese volunteers. Researchers monitored side effects, lab results, and vital signs over 7 days. The study does not …

This study measured how much of a brain protein called PDE10A is occupied by a single dose of TAK-063 in 13 healthy adult volunteers. Researchers used special brain scans (PET scans) to see the drug's effect at 3 and 23 hours after taking it. The goal was to understand how the dr…

This study observed 165 people with inflammatory bowel disease (Crohn's or ulcerative colitis) in Poland who were already taking or starting vedolizumab. Researchers tracked whether patients chose intravenous or subcutaneous (under-the-skin) injections, and how long they stayed o…

This study tracked 646 people with complex fistulas (abnormal tunnels) caused by Crohn's disease or other conditions. Researchers observed the standard surgical treatments patients received at their clinics and recorded outcomes like fistula closure and complications. The goal is…

This study looked at side effects of the drug niraparib (Zedula) in 354 people with ovarian cancer. Participants took niraparib capsules once a day as part of their normal care, and doctors recorded any side effects for one year. The main focus was on serious side effects like lo…

This study looked at how the body handles a single shot of fazirsiran in 34 people with mild, moderate, or severe liver problems, compared to those with healthy livers. Participants were followed for 6 months after the injection. The goal was to measure drug levels and check for …

This study aims to develop a computer algorithm that can detect Fabry disease earlier by analyzing hospital electronic health records. Researchers will look at data from the past 10 years to see if they can identify patients with Fabry disease using a ranking system. No drugs or …

This study looked back at medical records of 34 adults with von Willebrand disease (VWD) in the UK who received a newer treatment called vonicog alfa (rVWF). The goal was to see how well it controlled bleeding and was used during surgeries in real-world settings. No new treatment…

This study looked at the safety of the drug Ninlaro (ixazomib) when used to treat multiple myeloma in everyday medical practice in China. About 482 patients were observed, and researchers recorded any side effects or dose changes. The goal was to gather real-world safety informat…

This study reviewed medical records of 330 kidney transplant patients in the UK to understand how cytomegalovirus (CMV) infections are managed. Researchers looked at how common these infections are, what treatments were used, and how well they worked. The goal was to gather infor…

This study looked at medical records of 1,477 children in China diagnosed with central precocious puberty (early puberty). The goal was to see how many received treatment and how well it worked. No new treatments were tested—researchers simply collected existing information to un…

This study observed 92 adults with Crohn's disease or ulcerative colitis who were receiving vedolizumab either as an intravenous infusion or a subcutaneous injection. Researchers tracked treatment patterns, such as whether patients stayed on their current form or switched, over 1…

This early-stage study tested a new drug called TAK-004 in 121 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo as an injection under the skin. The study did not aim to treat any disease, but to gather important…

This early-phase study tested a drug called TAK-123 in 10 healthy Japanese men to see how the body absorbs and processes it, and whether it causes any side effects. The drug was given as an infusion, and researchers measured levels of its components in the blood. Since this was a…

This completed observational study followed 72 adults with moderate to severe Crohn's disease who were starting vedolizumab treatment. The goal was to see if the drug could lead to complete remission—meaning no symptoms, normal inflammation markers, and healed bowel walls—after 1…

This early-stage study tested how well healthy adults tolerate a new form of immune globulin (TAK-881) given under the skin with an enzyme that helps it spread. Sixty-four participants received different doses to see if they could complete the infusion without side effects. The g…

This completed study looked at 224 adults who already had at least one psychiatric condition to see how many also had undiagnosed ADHD. Researchers measured how often ADHD was missed and tracked quality of life in those diagnosed. The goal is to highlight the need for better dete…